European Leukemia Trial Registry
Trial: CML V (TIGER)

More Details
Title Tasigna and Interferon alpha evaluation initiated by the German CML Study Group
Scientific Title Treatment optimization of newly diagnosed Ph/BCR-ABL positive patients with chronic myeloid leukemia (CML) in chronic phase with nilotinib vs. nilotinib plus interferon alpha induction and nilotinib or interferon alpha maintenance therapy
Short Title CML V (TIGER)
Trialgroup CML-Studiengruppe
Type of Trial multicentric, randomized, open-label, double-group
Disease Chronic myeloid leukemia(CML) Chronic Phase
Age >= 18 years
Status No longer recruiting
Start of Recruitment 01.08.2012
Leader Hochhaus, Prof. Dr. med., Andreas
Contactperson

Study Physician
Hochhaus, Prof. Dr. med., Andreas
Tel: +49 (0)3641 932 4201
Fax: +49 (0)3641 932 4202
Email: andreas.hochhaus@med.uni-jena.de

Biometrics
Hasford, Prof. Dr. med., Jörg
Tel: +49 (0)89 57095 7481
Fax: +49 (0)89 57095 7482
Email: has@ibe.med.uni-muenchen.de
Homepage: http://www.ibe.med.uni-muenchen.de/

Biometrics
Pfirrmann, Dr., Markus
Tel: +49 (0)89 544201-40
Fax: +49 (0)89 544201-44
Email: pfi@ibe.uni-muenchen.de
Homepage: http://www.ibe.med.uni-muenchen.de/

eCRF
Gil, Arthur
Tel: +49 (0)89 7095 7487
Fax: +49 (0)89 7095 7491
Email: tiger-study@ibe.med.uni-muenchen.de

General Contact Person
Fabisch, Dr., Christian
Tel: +49 (0)3641 9-396670
Fax: +49 (0)3641 9-396669
Email: Christian.Fabisch@med.uni-jena.de

Centre of Trial Universitätsklinikum Jena, Klinik für Innere Medizin II, Abt. Hämatologie und Internistische Onkologie
Shortprotocol Shortprotocol
created 17.08.2012 Janina Rosemeier
changed 13.02.2018 Martina Wolkenfeld
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org